According to a new report North America Veterinary Oncology Market, published by KBV research, the North America Veterinary oncology Market would witness market growth of 12.4% CAGR during the forecast period (2020-2026).
The US market dominated the North America Feline Market by Country in 2019, and would continue to be a dominant market till 2026. The Canada market is poised to grow at a CAGR of 15.6% during (2020 - 2026). Additionally, The Mexico market would witness a CAGR of 14.7% during (2020 - 2026).
The Lymphoma market dominated the Mexico Veterinary Oncology Market by Cancer Type in 2019, thereby, achieving a market value of $3.8 million by 2026. The Mast Cell Cancer market is experiencing a CAGR of 13.2% during (2020 - 2026). The Mammary & Squamous Cell Cancer market would showcase a CAGR of 14.8% during (2020 - 2026).
The Chemotherapy market dominated the Canada Veterinary Oncology Market by Therapy in 2019, growing at a CAGR of 13.8 % during the forecast period. The Radiology market is estimated to grow at a CAGR of 14.1% during (2020 - 2026). Additionally, The Surgery market would showcase highest CAGR of 16.1% during (2020 - 2026).
Report Structural Insights: https://www.kbvresearch.com/north-america-veterinary-oncology-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.
By Animal Type
By Therapy
By Cancer Type
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
